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Abstract: 
Objective: to assess the cost-effectiveness of acupuncture in the management of 
chemotherapy-induced peripheral neuropathy in Hong Kong. 
Methods: A within trial cost-utility analysis with the primary endpoint for the economic 
evaluation being the Quality Adjusted Life Year (QALY) and associated Incremental 
Cost Effectiveness Ratio (ICER) over 14 weeks of treatment. A secondary cost-
effectiveness analysis was undertaken with the endpoint being change in pain as 
measured on the Brief Pain Inventory (BPI). 
Results: Eighty-seven patients were randomised to acupuncture or usual care. 
Acupuncture resulted in significant improvements in pain intensity (8 & 14 week mean 
changes compared to usual care of -1.8 & -1.8, respectively), pain interference (8 & 
14 week mean changes compared to usual care of -1.5 & -0.9, respectively) and 
indicators of quality of life and neurotoxicity-related symptoms. However, in the 
economic evaluation there was little difference in QALYs between the two arms (mean 
change 0.209 and 0.200 in the acupuncture and usual care arm respectively). Also, 
costs yielded deterministic ICERs of HK$616,965.62, HK$824,083.44 and 
HK$540,727.56 per QALY gained from the health care provider perspective, the 
societal perspective and the patient perspective, respectively. These costs are 
significantly higher than the cost-effectiveness threshold of HK$180,450 that was used 
for the base case analysis. 
Conclusion: While acupuncture can improve symptoms and quality of life indicators 
related to CIPN, it is unlikely to be a cost-effective treatment for CIPN-related pain in 
health care systems with limited resources. 
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Economic evaluation alongside a randomised controlled trial to assess the 
effectiveness and cost-effectiveness of acupuncture in the management of 
chemotherapy-induced peripheral neuropathy 
 
Introduction 
Acupuncture as an intervention to manage a broad range of conditions has shown 
promising and positive results over the years, from managing low back pain1, to 
functional dyspepsia2, migraine3, nausea/vomiting4 and others, although negative and 
inconclusive evidence does exist for other conditions4. Economic evaluations 
increasingly underpin decisions in health care about allocation of resources and as 
such they should be incorporated in all trials of new interventions. However, the cost-
effectiveness of acupuncture has received little attention in the literature, with a small 
body of evaluations showing that at times it can be cost-effective and at times it is not. 
Systematic reviews support the cost-effectiveness of acupuncture for chronic pain5, 
dysmenorrhoea, allergic rhinitis, in osteoarthritis or headache6. On the other hand, 
several studies showed that acupuncture was not cost-effective, including in the 
management of irritable bowel syndrome7, chronic low back pain (unless comorbid 
depression was included)8 or allergic rhinitis9. 
 
Chemotherapy- induced peripheral neuropathy (CIPN) is a derangement in structure 
and function of peripheral motor, sensory and autonomic neurons, causing peripheral 
neuropathic signs and symptoms10. The prevalence of CIPN is reported to be 10-20% 
in patients during treatment and it may be as high as 100%, depending on the 
chemotherapy drug, dose-intensity, cumulative dose and other as yet unidentified risk 
factors11,12. CIPN has significant implications for patients’ quality of life13 alongside an 
impact on health care resource use, with those experiencing CIPN having more often 
outpatient visits and medication use, estimated to be at US$17,000 more in patients 
with CIPN than non-CIPN cancer patients14.The management of CIPN is difficult with 
a limited number of treatment options available. There are some small-scale studies 
providing some initial evidence of effect, particularly in decreasing neuropathic pain, 
reviewed by Franconi15. We have recently completed the first fully-powered 
randomised trial in the management of chemotherapy-induced peripheral 
neuropathy16. Within this trial, we also assessed the cost-effectiveness of the use of 
acupuncture alongside usual care, versus usual care only, to allow for more informed 
health care decisions to be made in the future. Our trial included 87 patients 
randomised to acupuncture or usual care for 8 weeks16. The primary outcome for the 
trial was pain intensity or pain interference over the past week and secondary 
outcomes included patient-reported outcome measures with assessments taking 
place at baseline, end of treatment and week 14 from the beginning of treatment. At 
the end of the intervention, there were significant improvements in the acupuncture 
arm both in terms of primary and secondary outcomes. At 14 weeks there were still 
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significant improvements in pain interference, neurotoxicity-related symptoms and 
functional aspects of quality of life (p<0.05) and at 20 weeks improvements sustained 
with regards to physical and functional well-being (p<0.05). In this article, we examined 
the cost-effectiveness of acupuncture in the management of CIPN with respect to cost 
per quality-adjusted life years (QALYs) and cost per unit reduction in pain intensity 
and pain interference, compared to usual care, over 14 weeks from randomisation. 
 
Methods 
The parent trial was an assessor-blinded randomised controlled trial of acupuncture 
for 8 weeks compared to a waitlist control arm receiving standard care, the latter group 
receiving acupuncture at the end of the trial. Adult patients having received neurotoxic 
chemotherapy and reporting numbness/tingling in the hands/feet and having signs of 
neuropathy according to their medical practitioner, were eligible to participate. Primary 
outcome was ‘worst pain’ using the Brief Pain Inventory (BPI)17. Other outcomes 
include the BPI pain interference item and the Functional Assessment of Cancer 
Therapy (FACT/GOG-Ntx)18.  
Measurement and valuation of outcomes 
To determine the intervention’s cost-effectiveness, we assessed the impact of the 
intervention on quality of life and reduction in pain over 14 weeks.  
Quality of life was measured using the 27 item general assessment of quality of life 
sub-scale (FACT-G) of the Functional Assessment of Cancer Therapy (FACT/GOG-
Ntx)18. The FACT-G questionnaire was completed by patients at home at baseline, at 
the end of the 8 weeks treatment and at 14 weeks post randomisation. Patient 
responses to the FACT-G questionnaire were converted to utility values using a 
mapping algorithm to convert to the EQ-5D scale and utility values relevant to the 
Chinese population19. The equation used was the following: 
EQ-5D utility index = 0.238 + (0.014 x GP) + (0.006 X GE) + (0.008 X GF) 
Where, GP is physical, GE is emotional and GF is functional well-being.  
The utility values represent patients’ quality of life and were multiplied by duration (t) 
in each health state to generate quality adjusted life years (QALYs)20. An area under 
the curve (AUC) approach was adopted for estimating QALYs with a linear transition 
assumed between adjacent time points. 
 
ܳܣܮܻ ൌ ൭൬ܷݐ݈݅݅ݐݕ஻௔௦௘௟௜௡௘ ൅ ܷݐ݈݅݅ݐݕ଼2 ൰ ∗ ݐ൱ ൅ ൭൬
ܷݐ݈݅݅ݐݕ଼ ൅ ܷݐ݈݅݅ݐݕଵସ
2 ൰ ∗ ݐ൱ 
Where, ܷݐ݈݅݅ݐݕ஻௔௦௘௟௜௡௘, ܷݐ݈݅݅ݐݕ଼ and ܷݐ݈݅݅ݐݕଵସ are the utility scores at baseline, week 8 
and week 14, respectively. 
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The secondary outcome measure was reduction in pain as measured by the ‘worst 
pain during the past week’ measured on the Brief Pain Inventory (BPI), completed by 
patients at each time point. Reduction in pain was calculated at 8 and 14 weeks (with 
respect to baseline) on the two dimensions of the BPI questionnaire: pain severity and 
pain interference. The Pain Severity subscale is calculated as the mean of four pain 
items, from question 3 to 6; and the Pain interference subscale is calculated as the 
mean of the seven interference items, from question 9a to 9g. 
Measurement and valuation of resource use 
Costs related to the intervention and wider healthcare utilisation 
Healthcare resource use was estimated from the perspective of the healthcare 
provider and was collected for the trial period of 14 weeks from randomisation. This 
included primary care such as GP, nurse visits and home visits as well as secondary 
care such as outpatient visits and other hospital admissions. Additionally resource use 
and cost data from a patient perspective were obtained to enable analyses from 
patient and societal perspectives. The healthcare provider perspective included the 
costs to provide medical treatments. The patient perspective included costs for 
healthcare treatment and services, medications (paid for by patient), travel costs, food 
and drink costs and other expenses related to treatment that were paid for out of 
pocket. The societal perspective included all costs for healthcare, patient perspective 
costs and also costs associated with productivity loss from time out of work due to 
illness. 
Resource use was captured using a bespoke questionnaire which patients completed 
at 14 weeks post randomisation. To determine the costs associated with the 
intervention and wider healthcare utilisation, unit costs were assigned to healthcare 
resource use using charge values from the Hospital Authority of Hong Kong21, and 
price year 2017. Charges are made up of two parts, part paid by the patient and part 
paid by the insurer. The sum of these two charges was used as the total cost of the 
relevant healthcare service. Costs were assigned on a per unit basis, with unit values 
taken from the resource use data collected within the trial. All recorded use of 
healthcare services that occurred within the trial period were costed irrespective of 
whether their use was directly associated with the treatment of cancer or the 
associated neuropathy. Unit costs for the main resource use items are presented in 
Table 1. Patient’s use of healthcare resources and total costs were calculated for the 
intention-to-treat (ITT) population.  
Cost-effectiveness analysis 
Primary analysis 
The primary analysis was a cost-utility analysis in which an incremental cost per QALY 
gained, due to acupuncture compared to usual care, was calculated over 14 weeks. 
As the intervention is intended to limit the side-effects of the chemotherapy, the 
benefits are not expected to continue after treatment has ceased and consequently 
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this short time-horizon is appropriate for the research question being explored. For the 
main analysis, a healthcare provider perspective was adopted; a patient perspective 
and a societal perspective were also adopted for subsequent analyses. As the 
timeframe of the trial was less than a year, discounting of the costs and benefits was 
not required. 
The incremental cost per QALY gained as a result of the use of acupuncture 
compared to usual care was calculated by dividing the mean difference in cost of the 
two trial arms by the mean difference in QALYs to produce an incremental cost-
effectiveness ratio, as follows: 
ܫܥܧܴ ൌ ሺܥ݋ݏݐ஺ െ ܥ݋ݏݐ஻ሻ/ሺܳܣܮ ஺ܻ െ ܳܣܮ ஻ܻሻ 
The ICER represents the additional cost per QALY gained for the intervention 
compared to the best alternative (in this case usual care) 22. 
After considering that, first, a single ICER threshold value for decision making is not 
officially available in Hong Kong and, second, the gross domestic product per capita 
threshold is no longer recommended by World Health Organisation23, the cost-
effectiveness threshold was set at $23,105 based on a research paper by Woods et 
al.24 on country-level cost-effectiveness thresholds. The paper indicates a threshold 
range for Hong Kong of $17,409 - $28,801; hence the midpoint was selected as the 
reference threshold. This threshold range was converted to Hong Kong dollars using 
an exchange rate of 1 US dollar=7.81 Hong Kong dollars to give HK$135,964 - 
HK$224,936. The mid-point of HK$180,450 was used as the cost-effectiveness 
threshold for the base case analysis. (In line with current best practice for economic 
evaluation, we did not adjust the cost-effectiveness threshold with respect to inflation 
(Drummond et al, 2015; Claxton et al, 2015)). Alternative thresholds were explored in 
the uncertainty analysis. 
Secondary analysis 
In the secondary cost-effectiveness analysis, the incremental cost was compared to 
the change in BPI scores, in the two pain subscales, between baseline and 8 weeks 
as well as baseline and 14 weeks, as a result of the use of acupuncture compared to 
usual care. 
Missing Data 
Where patients indicated they had used a particular health care service but had not 
recorded the number of times it had been used, the mean of visits to that health service 
was imputed. For the BPI, only 25 patients responded “YES” to the first question 
(“Throughout our lives, most of us have had pain from time to time. Have you had pain 
other than these everyday kinds of pain today?”) and were prompted to answer the 
remaining items. Hence, in the original dataset, only these 25 subjects had a BPI score 
while the others showed missing values. It was agreed that those who responded “No” 
in the first question should have a BPI score of ‘0’, so the missing values were imputed 
with zeros. 
Commented [BD1]: Alex please can you add these 
references, I didn’t want to mess up the formatting: 
 
Drummond, M.F., Sculpher, M.J., Claxton, K., Stoddart, 
G.L. and Torrance, G.W. 2015. Methods for the economic 
evaluation of health care programmes.  Oxford university 
press. 
 
Claxton, K, Martin, S, Soares, M, Rice, N, Spackman, E, 
Hinde, S, Devlin, N, Smith, PC & Sculpher, M 2015, 
'Methods for the estimation of the National Institute for 
Health and Care Excellence cost-effectiveness 
threshold', Health technology assessment, vol. 19, no. 
14, pp. 1-542. https://doi.org/10.3310/hta19140 
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Multiple imputation was employed to account for missing EQ-5D data. This approach 
is recommended for economic analyses conducted alongside clinical trials as it reflects 
the uncertainty inherent in replacing missing data25. The imputation was performed in 
Stata Version 14 using predictive mean matching to perform multiple imputation by 
chained equations. Predictive mean matching was used due to the non-normal 
distribution of EQ-5D scores. This technique ensures that only plausible values of the 
missing variable are imputed as the imputed value is drawn from another individual 
whose predicted value is close to the predicted value of the individual with the missing 
observation26.	
Sensitivity Analyses 
Alternate scenarios were explored in the sensitivity analyses to test the robustness of 
the main trial analysis results. The effect of not imputing missing quality of life data 
was explored with an analysis including only complete cases. Additionally, sensitivity 
analyses were performed to explore the uncertainty around the costs by adding and 
subtracting 20% of the costs and outcomes and assessing the subsequent impact on 
the ICERs. The value of 20% is essentially arbitrary but was considered likely to 
represent any uncertainty that might exist in the values. The increase and decrease in 
costs by 20% was explored both from the health care provider perspective and the 
societal perspective.  
Further sensitivity analyses were conducted to explore the effect of assumptions made 
in the base case analysis related to patient perspective costs. In the base case 
analysis, it was assumed that the costs reported for prescription medications were 
related only to the trial period, not for the whole time the medication was taken. The 
effect of this was explored in a sensitivity analysis in which it was assumed that the 
reported cost was for the whole time the medication was taken and the relevant cost 
for the trial period was calculated as the total cost divided by the number of days taken 
to estimate a cost per day which was multiplied by 98 (98 days equal to 14 weeks – 
the length of the trial). In the base case analysis it was also assumed that the treatment 
cost was paid by the patient out-of-pocket. The effect of this was explored in a 
sensitivity analysis in which it was assumed that the treatment was paid for by an 
insurer/ public provider instead of by the patient.  
Additional sensitivity analysis was also performed to explore the robustness of the 
secondary analysis results. The secondary analysis was based on changes in BPI (the 
primary outcome of the main trial analysis). As only a small number of patients had 
the primary outcome, the effect of acupuncture on other neurotoxic symptoms was 
also explored in a sensitivity analysis which instead used the outcome of neurotoxicity 
from the subscale of FACT/GOG. 
Uncertainty Analysis 
The level of sampling uncertainty around the ICER was determined using a non-
parametric bootstrap to generate 10,000 estimates of incremental costs and benefits. 
The bootstrapped estimates were plotted on the cost-effectiveness plane to illustrate 
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the uncertainty surrounding the cost-effectiveness estimates27. Net monetary benefit 
was calculated for each of the bootstrapped estimates as: 
ܰܯܤ ൌ ሺλ ൈ ܳܣܮܻݏሻ െ ܿ݋ݏݐݏ 
Where, λ is the value a decision maker would be willing to pay per incremental QALY 
gained, i.e. the cost-effectiveness threshold. 
The expected net monetary benefit was used to estimate the probability that 
acupuncture is cost-effective given a range of threshold values (λ=£0 to λ =£100,000) 
which is plotted on the cost-effectiveness acceptability curve (CEAC)28. The cost-
effectiveness frontier (CEF) was also plotted to show the intervention that provides the 
highest net benefit for a given threshold. 
 
Ethical approval 
Ethical approval was granted by the Human Research Ethics Review Committee of 
the Hong Kong Polytechnic University (HSEARS20141011004; approved 29 October 
2014) and the study hospital (CREC Ref. 2014.529-T; approved 18 November 2014) 
All participants signed a consent form. The trial was prospectively registered with 
ClinicalTrials.gov, identifier: NCT02553863. 
 
Results 
Sample 
The first patient was recruited in November 2015, recruitment was completed in 
March 2017 and last patient follow-up was completed in May 2017. Among the 87 
participants, the acupuncture arm had a higher share of male patients (62.5%), while 
in the usual care arm there was a higher share of female patients (55.6%). The 
mean age was 56.3 (SD=7.35) years old in the acupuncture arm and 58 (SD=7.98) 
in the usual care arm. 
 
Resource use and costs 
Resource use and costs incurred by patients in each arm are presented in Table 2. 
Average total healthcare costs were HK$8,849 and HK$3,286, for the acupuncture 
and usual care arms of the trial, respectively, meaning that patients receiving the 
intervention, on average, showed higher total cost associated with the use of health 
care services (primarily due to the acupuncture costs). Also, based on the control 
arm costs above (over 14 weeks), if costs remain constant, patients with CIPN cost 
the healthcare system HK$12,205 (US$1,565) annually.  
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Outcomes 
Mean QALYs gained from baseline to 14 weeks were 0.209 and 0.200 for 
acupuncture and usual care, respectively (presented in Table 3). In the usual care 
arm, the change from baseline regarding pain severity increased 0.5 points from 
baseline to 8 weeks and increased1 point from baseline to 14 weeks, while for the 
acupuncture arm these –decreased by 1.3 points and 0.8, respectively. Pain 
interference increased 0.5 points from baseline to week 8 and  increased 0.8 points 
from baseline to week 14, whereas in the acupuncture group pain interference 
decreased by  1 and 0.1 points, respectively. Mean BPI scores are presented in 
Supplementary Table 1.  
 
Cost-effectiveness analysis 
Primary analysis 
The cost-effectiveness results estimated from the healthcare provider perspective, the 
societal perspective and the patient perspective are each presented in Table 1. The 
QALYs and costs yielded deterministic ICERs of HK$616,965.62, HK$824,083.44 and 
HK$540,727.56 per QALY for the health care provider perspective, the societal 
perspective and the patient perspective, respectively. 
The healthcare provider perspective was taken as the base case analysis which was 
used to perform uncertainty analysis around the cost-effectiveness estimates. 
Bootstrapped uncertainty analysis produced a cloud of points which is predominantly 
in the north-east quadrant and entirely above the threshold, with a mean simulation 
ICER of HK$598,289.19 (Figure 1). The CEAC in Figure 2 suggests that acupuncture 
had 6% probability of being cost-effective at the HK$180,450 threshold. 
INSERT TABLE 1 & FIGURE 1 & FIGURE 2 HERE 
 
Secondary Analysis 
Regarding BPI change over time compared to baseline, the cost-effectiveness results 
estimated for the two subscales (pain severity and pain interference) and over two 
time periods (8 and 14 weeks) are shown in Table 2. The assumption was made that 
the costs incurred are evenly spread across the trial period; therefore a proportion was 
used for the cost-effectiveness analysis over 8 weeks. The results show that 
acupuncture is most cost-effective in reducing pain severity from baseline to 8 weeks. 
INSERT TABLE 2 HERE 
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Sensitivity analysis 
The cost-effectiveness results for each scenario explored in the sensitivity analyses 
are presented in Table 3. In each case the results of the sensitivity analysis, for both 
the healthcare provider perspective and the societal perspective, support the results 
of the base case analysis and indicate that, compared to a cost-effectiveness 
threshold value of HK$180,450, acupuncture alongside usual care for the 
management of chemotherapy-induced peripheral neuropathy is not a cost-effective 
use of health care resources. 
For patient perspective costs, alternative assumptions around the costs of prescription 
medication had little impact on the ICER estimates. However, the cost of acupuncture 
appears to be a key driver of the difference in patient costs between the control and 
intervention arms of the trial. When it is assumed that treatment (acupuncture) is paid 
for by an insurer or public provider, there is no significant difference in patient out of 
pocket costs between the 2 arms (p=0.87).  
Sensitivity analysis exploring the impact of considering other neurotoxic symptoms is 
also shown in Table 3. As in the analysis of BPI, estimates of cost-effectiveness are 
presented for the periods: baseline to 14 weeks, and baseline to 8 weeks. Costs 
incurred were assumed to be evenly spread across the trial period and therefore a 
proportion of the 14 week costs were used for the cost-effectiveness analysis over 8 
weeks. The results confirm the robustness of the secondary analysis with BPI mean 
score showing that acupuncture is most cost-effective in reducing symptoms of 
neurotoxicity from baseline to 8 weeks. 
INSERT TABLE 3 HERE 
 
Discussion 
This is the first health economic analysis of acupuncture for managing CIPN. While 
the trial showed acupuncture to be an effective treatment of CIPN in relation to pain 
and other neuropathic symptoms and quality of life indicators, the results of the 
economic evaluation indicated that the probability of acupuncture being cost-effective 
is 6%. The cost of acupuncture appears to be a key driver of the difference in patient 
costs between the control and intervention arms of the trial, a finding of other studies 
where acupuncture was effective but not necessarily cost-effective [9]. On the other 
hand, there was little difference in QALYs gained between the two arms despite 
benefits in terms of pain reduction. On this point, it is worth considering that the EQ-
5D is a generic measure of quality of life and may not be sensitive enough to pick up 
these changes in quality of life. Also QALYs were estimated using a mapped algorithm 
for EQ-5D. Although this was validated for the Chinese/Hong Kong population, this 
could be a source of bias. The sensitivity analyses conducted supported the results of 
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the base case analysis and indicate that, compared to a cost-effectiveness threshold 
value of HK$180,450, acupuncture alongside usual care for the management of CIPN 
is not a cost-effective use of resources. However, pain in this sample was mild 
(mean=1.2; 2.1, sd=0.3; 0.4 in the control and intervention groups respectively) and 
this may be a reason for the small clinical changes observed, reflected in a non-cost 
effective outcome in this evaluation. The low levels of pain experienced by patients 
recruited in this study poses a limitation to the analysis as consequently healthcare 
resource use may have been lower than in other similar patient groups. 
The results of the secondary cost-effectiveness analysis suggested that acupuncture 
reduces pain severity and pain interference over both 8 and 14 weeks but that it is 
most cost-effective in reducing pain severity from baseline to 8 weeks. As the key 
issue is the actual acupuncture cost, it indicates that for patients with health insurance 
that will cover the cost of the treatment, the patient can obtain the benefits of the 
treatment with little additional out-of-pocket costs. However, this may raise an equity 
issue for those patients who do not have appropriate health insurance as their out-of-
pocket costs to obtain this treatment may be much higher. Access to acupuncture 
treatment may also be an issue, particularly in rural areas, as patients may be willing 
to pay for such an effective service but there is unavailability of acupuncture delivery. 
In addition, given that the cost of acupuncture is a key diver of the difference in cost 
between groups, and that the cost of acupuncture varies in different countries, the 
cost-effectiveness of acupuncture for CIPN will vary in different countries and contexts. 
It is important to note that the treatment comparator used in an acupuncture trial can 
be fundamental as to whether the acupuncture will be cost-effective or not. In our case, 
the treatment comparator was usual care, which in reality involved very little supportive 
care and primarily painkillers if there was any pain or vitamin B. If the comparator was 
another treatment, the results may have been different. Also, more wide use of 
acupuncture in a clinical setting may decrease the costs of treating CIPN patients. 
Furthermore, this economic conclusion is tentative as we have not assessed long-term 
costs beyond 14 weeks, and if symptoms have not reverted to baseline beyond the 
14-week assessment it is possible that functioning may have improved and cost-
effectiveness may become more likely. 
Lastly, an important consideration is that cost-effectiveness is determined by the cost-
effectiveness threshold and there is no pre-defined cost-effectiveness threshold for 
Hong Kong. We used the threshold from Woods et al [23] as it provides a plausible 
estimate of health opportunity cost in Hong Kong. However note that further research 
would be of use to estimate appropriate cost-effectiveness thresholds for Hong Kong 
given the unique healthcare landscape and accounting for decision making from 
different perspectives (e.g. healthcare provider, department of health, insurer etc)29. 
The choice of threshold will impact the results and it may be helpful for decision makers 
to use the CEAC to explore potential cost-effectiveness for cost-effectiveness 
thresholds relevant to their specific decision making context. 
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Conclusion 
The economic evaluation indicated that acupuncture alongside usual care for the 
management of chemotherapy-induced peripheral neuropathy, while effective for 
managing pain and other neuropathic symptoms and improving quality of life, is 
unlikely to be a cost-effective use of healthcare resources when compared with a cost-
effectiveness threshold based on opportunity costs elsewhere in the system. 
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Table 1 Unit costs of health care services 
Resource item Patient charge 
(HKD) 
Insurance charge 
(HKD) 
Source Details 
GP surgery visit $50 $445 Hospital Authority General clinic 
GP home visit $80 $445 Hospital Authority General clinic 
District nurse 
surgery visit 
$80 $535 Hospital Authority Community nursing 
service 
District nurse home 
visit 
$80 $535 Hospital Authority Community nursing 
service 
Oncology specialist 
visit 
$135 first visit, $80 
subsequent visits 
$1190 Hospital Authority Specialist clinic 
Hospital oncology 
clinic 
$96 $895 Hospital Authority Clinical oncology 
clinic 
Psychologist $60 $1730 Hospital Authority Psychiatric day 
hospital 
Physiotherapist $55 $1730 Hospital Authority Rehabilitation day 
hospital 
Occupational health 
visit 
$55 $1730 Hospital Authority Rehabilitation day 
hospital 
Dermatologist $135 first visit, $80 
subsequent visits 
$1190 Hospital Authority Specialist clinic 
Traditional Chinese 
medicine 
practitioner 
$50 $445 Hospital Authority General clinic 
Other hospital 
departments: 
internal medication, 
blood taking 
$19 $100 Hospital Authority Hospital 
attendance for 
injection or 
dressing 
Notes:  
1, Data was collected on contacts with healthcare services by telephone or email (reported below) but no 
costs are included in the analysis for these services as they are not charged for. 
 
Table 2 Resource use and costs 
Healthcare 
Resource use 
Mean (SD) Patient cost Mean (SD) 
Hospital cost Mean 
(SD) 
Usual 
care 
Acupun
cture Usual care 
Acupunctur
e 
Usual 
care 
Acupunct
ure 
GP 
0.49 
(0.86) 
0.98 
(1.92) 
24.42 
(0.86) 48.86 (96.14) 
217.33 
(0) 
434.89 
(855.64) 
GP (home) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
District nurse 0 (0) 0 (0) 0 (0) 0 (0) 0 (1.37) 0 (0) 
District nurse (home) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Oncology hotline1 0 (0) 
0.14 
(0.51) 0 (0) 0 (0) 0 (0) 0 (0) 
Oncology specialist 
0.12 
(0.39) 
0.5 
(1.21) 14.42 (0) 52.5 (115.76) 
138.37 
(4.05) 
595 
(1440.4) 
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Oncology specialist 
(home) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Hospital oncology 
unit 
1.51 
(3.59) 
1.5 
(4.28) 
145.12 
(0.39) 144 (410.7) 
1352.91 
(0.15) 
1342.5 
(3828.92) 
Psychologist/Psychia
trist 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Psychologist/Psychia
trist (home) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Physiotherapist 
0.21 
(1.37) 
0.32 
(1.07) 11.51 (0) 17.5 (59.04) 
362.09 
(42.78) 
550.45 
(1857.01) 
Physiotherapist 
(home) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Other 
2.02 
(4.05) 
2.56 
(6.25) 
98.84 
(3.59) 
102.98 
(208.9) 98.84 (0) 
102.98 
(208.9) 
Treatment 
(acupuncture)2 - - 0 (0) 
4697.73 
(589.24) - - 
Prescription 
medication3 - - 1028.74 (0) 
1194.32 
(3132.55) - - 
Non-prescription 
medication3 - - 
789.35 
(46.79) 
959.82 
(2794.78) - - 
Travel4 - - 
471.4 
(345.1) 401 (518.84) - - 
Food and drink5 - - 
1631.98 
(75.49) 
952.5 
(1236.83) - - 
Other expenses5 - - 
3702.14 
(203.39) 
4223.64 
(15236.42) - - 
Productivity loss 
(days)6 50 (0) 
55.11 
(45.65) 
15852.27 
(380.73) 
17789.77 
(24003.07) - - 
Notes: 
1 Oncology hotline is a free service;  
2 The treatment cost is assumed to fall to patients if implemented in practice (outside of trial 
setting);  
3 These were reported as patient costs, no itemised prescription data was available;  
4 The sum of out of pocket costs for taxis, public transport, fuel, additional miles and parking; 
5 Cost data reported only;  
6 calculated using a human capital approach based on days out of work and associated income 
 
Table 2 Cost-effectiveness analysis 
Treatment 
group 
Cost (HKD$) 
Mean (SD) 
Incremental 
cost 
QALYs 
Mean (SD) 
Incremental 
QALYs 
ICER (HK$/ 
QALY) 
Health care provider perspective 
Usual care $3,286.16 
(6009.04)  0.200 (0.022)   
Acupuncture $8,849.25 (6182.91) $5,563.09 0.209 (0.021) 0.009 $616,965.62 
Societal perspective 
Usual care $12,384.40 (19230.74)  0.200 (0.022)   
Acupuncture $19,815.03 (22955.75) $7,430.63 0.209 (0.029) 0.009 $824,083.44 
Patient perspective 
Usual care $7,919.19 (17636.65)  0.200 (0.022)   
Acupuncture $12,794.84 (17793.87) $4,875.65 0.209 (0.029) 0.009 $540,727.56 
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Table 3 Cost-effectiveness in reducing pain 
Treatment 
group 
Cost (HKD$) 
Mean  
Incremental 
cost 
Mean change 
in BPI score 
from baseline 
Incremental 
change in BPI  
ICER (HK$/unit 
reduction BPI 
score) 
14w change Pain Severity 
Usual care $3,286.16   1.0    
Acupuncture $8,849.25  $5,563.09 -0.8 -1.8 $3,090.60 
14w change Pain Interference 
Usual care $3,286.16  0.8    
Acupuncture $8,849.25  $5,563.09 -0.1 -0.9 $6,181.21 
8w change Pain Severity 
Usual care $1,877.80  0.5   
Acupuncture $5,056.71  $3,178.91 -1.3 -1.8 $1,766.06 
8w change Pain Interference  
Usual care $1,877.80  0.5   
Acupuncture $5,056.71  $3,178.91 -1 -1.5 $2,119.27 
 
 
 
 
 
 18 
 
Table 4: Sensitivity analysis – cost-effectiveness results 
Treatment Group Cost ($HKD) 
Mean (SD) 
Incremental 
cost 
QALY 
Mean (SD) 
Incremental 
QALY 
ICER 
(HK$/QALY) 
Health care provider perspective: Complete case analysis 
Usual care n=39 3597.82 
(6230.45) 
 0.1997 (0.03)   
Acupuncture n=42 9134.93 
(6169.93) 
5537.11 0.2087 (0.022) 0.0089 618,280.5 
Health care provider perspective: 20% increase costs 
Usual care n=43 3943.40 
(7210.85) 
 0.2003 (0.029)   
Acupuncture n=44 10619.1 
(7419.49) 
6675.70 0.2093 (0.022) 0.0090 740,359.50 
Health care provider perspective: 20% decrease costs 
Usual care n=43 2628.93 
(4807.24) 
 0.2003 (0.029)   
Acupuncture n=44 7079.40 
(4946.33) 
4450.47 0.2093 (0.022) 0.0090 493,573.03 
Societal perspective: 20% increase in costs 
Usual care n=43 14861.28 
(23076.89) 
 0.2003 (0.029)   
Acupuncture n=44 23778.03 
(27546.9) 
8916.75 0.2093 (0.022) 0.0090 988,899.94 
Societal perspective: 20% decrease in costs 
Usual care n=43 9907.52 
(15384.59) 
 0.2003 (0.029)   
Acupuncture n=44 15852.02 
(18364.6) 
5944.50 0.2093 (0.022) 0.0090 659,266.75 
Patient perspective: Prescription medication cost for whole duration prescribed 
Usual care n=43 7909.76 
(17626.42) 
 0.2003 (0.029)   
Acupuncture n=44 12718.82 
(17820.43) 
4809.05 0.2093 (0.022) 0.0090 533,341.81 
Patient perspective: Treatment (acupuncture) paid for by insurer/ public provider 
Usual care n=43 7919.19 
(17636.65) 
 0.2003 (0.029)   
Acupuncture n=44 8097.11 
(17738.34) 
177.93 0.2093 (0.022) 0.0090 19,732.82 
14w change in FACT/GOG NtxS (from baseline) 
Usual care $3,286.16   0.96   
Acupuncture $8,849.25  $5,563.09 3.23 2.27 $2,446.73 
8w change in FACT/GOG NtxS (from baseline) 
Usual care $1,877.80  1.73   
Acupuncture $5,056.71  $3,178.91 4.90 3.16 $1,005.98 
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Supplementary table 1: BPI mean scores 
Variable Usual care (n=43) Acupuncture (n=44)
baseline   
Pain Severity 1.3 2.1 
Pain interference 0.9  1.4  
8 weeks   
Pain Severity 1.8  0.8  
Pain interference 1.4  0.4  
14 weeks   
Pain Severity 2.3  1.3  
Pain interference 1.7  1.3 
 
